A systematic literature review of the human skin microbiome as biomarker for dermatological drug development by Niemeyer - van der Kolk, T. (Tessa) et al.
SYSTEMATIC REVIEW AND META–ANALYSIS
A systematic literature review of the human
skin microbiome as biomarker for
dermatological drug development
Correspondence Robert Rissmann, PhD, Centre for Human Drug Research, Zernikedreef 8, 2333CL Leiden, the Netherlands; Tel. +31
(0)71 5246400, Fax. +31 (0)715246499; E-mail: rrissmann@chdr.nl
Received 24 January 2018; Revised 9 May 2018; Accepted 11 May 2018
T. Niemeyer - van der Kolk1,2 , H. E. C. van der Wall1, C. Balmforth1, M. B. A. Van Doorn1,2 and
R. Rissmann1,3,4
1Centre for Human Drug Research, Leiden, the Netherlands, 2Department of Dermatology Erasmus MC, University Medical Center Rotterdam, the
Netherlands, 3Leiden University Medical Center, Leiden, the Netherlands, and 4Leiden Academic Center for Drug Research, Leiden, the Netherlands
Keywords biomarkers, clinical drug development, microbiota, surrogate parameter
AIMS
To explore the potential of the skin microbiome as biomarker in six dermatological conditions: atopic dermatitis (AD), acne
vulgaris (AV), psoriasis vulgaris (PV), hidradenitis suppurativa (HS), seborrhoeic dermatitis/pityriasis capitis (SD/PC) and ulcus
cruris (UC).
METHODS
A systematic literature review was conducted according to the PRISMA guidelines. Two investigators independently reviewed the
included studies and ranked the suitability microbiome implementation for early phase clinical studies in an adapted GRADE
method.
RESULTS
In total, 841 papers were identiﬁed and after screening of titles and abstracts for eligibility we identiﬁed 42manuscripts that could
be included in the review. Eleven studies were included for AD, ﬁve for AV, 10 for PV, two for HS, four for SD and 10 for UC. For AD
and AV, multiple studies report the relationship between the skin microbiome, disease severity and clinical response to treatment.
This is currently lacking for the remaining conditions.
CONCLUSION
For two indications – AD and AV – there is preliminary evidence to support implementation of the skin microbiome as biomarkers
in early phase clinical trials. For PV, UC, SD and HS there is insufﬁcient evidence from the literature. More microbiome-directed
prospective studies studying the effect of current treatments on the microbiome with special attention for patient meta-data,
sampling methods and analysis methods are needed to draw more substantial conclusions.
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Introduction
The escalating number of therapeutic candidates in drug de-
velopment programs require strategies that optimize the pro-
cess of clinical development. A common approach is the use
of biomarkers in clinical trials. A biomarker is deﬁned as a
characteristic that can be objectively measured and evaluated
as an indicator of normal biological processes, pathogenic
processes or pharmacological responses to a therapeutic in-
tervention [1, 2]. Clinical biomarkers are thought to reﬂect
disease activity and pathophysiology [3, 4]. A useful bio-
marker in any class has to comply with the following general
criteria: (i) there must be a consistent response of the bio-
marker across studies (preferably from different research
groups) and drugs from the same mechanistic class; (ii) the
biomarker must respond clearly to therapeutic (not
supratherapeutic) doses; (iii) there must be a clear dose- or
concentration-response relationship; and (iv) there must a
plausible relationship between the biomarker, pharmacology
of the drug class and disease pathophysiology [4]. Validated
biomarkers are often being used to guide drug development
programmes from human pharmacology studies, i.e. phase
1 trials, to conﬁrmatory trials, i.e. phase 3 studies [2]. For der-
matological diseases the drug developers often rely on clinical
efﬁcacy scores, e.g. the Eczema Area and Severity Index (EASI)
for atopic dermatitis (AD), Psoriasis Area and Severity Index
for psoriasis vulgaris (PV) and inﬂammatory lesion count for
acne vulgaris (AV) or investigator global assessments. How-
ever, more objective outcome measures including validated
biomarkers would have great added value in this ﬁeld. One
of these potential new biomarkers is the human skin
microbiome, which has the potential to monitor disease ac-
tivity and drug speciﬁc (mechanistic) effects.
The human microbiome refers to the combined genomic
information of all microbial communities living on or in
the human body. Collectively, this encompasses fungi
(mycobiota), bacteria (microbiota), viruses, bacteriophage,
archaea and protozoa. This, along with the human genome,
completes what is now termed the human microbial superor-
ganism [5]. The skin microbiome harbours vast microbial
communities living in a range of both physiologically and to-
pographically distinct niches and microenvironments [6, 7].
Actinobacteria (52%), Firmicutes (24%), Proteobacteria
(17%) and Bacteroidetes (7%) are the four most abundant
species identiﬁed on the skin [8]. Previous studies have
shown that it is not only skin topography that inﬂuences mi-
crobial colonization, but also a vast range of host-speciﬁc fac-
tors including age and sex, and environmental factors such as
occupation, clothing choice, antibiotic use, cosmetics, soaps,
environmental temperature, humidity, and longitudinal
and/or latitudinal variation in UV exposure, which can all
contribute to the variability seen in the microbial ﬂora of
the skin [9–15]. Moreover, changes or aberrations in the skin
microbiome have been implicated in the pathophysiology of
numerous skin diseases such as AD and AV [16].
Several reviews have described the role and impact of skin
microbiome on disease [17–22]. However, to date, no struc-
tured review has been conducted to evaluate the feasibility,
suitability and potential use of the skin microbiome as bio-
marker for early phase clinical drug development. Therefore,
we conducted a systemic literature review with predeﬁned
search terms according to the PRISMA guidelines, with focus
on six relevant disorders, i.e. AD, seborrhoeic dermatitis and
pityriasis capitis (dandruff; SD/PC), AV, hidradenitis
suppurativa (HS), PV and ulcus cruris/chronic wounds (UC).
In addition, we evaluated and ranked the conditions regard-
ing the potential as clinical biomarker. Lastly, we provided
recommendations for prospective microbiome investigations
in clinical drug development programmes.
Methods
We followed the Preferred Reporting Items for Systematic Re-
views and Meta-analysis (PRISMA) [23]. In collaboration with
a trained librarian from the Leiden University Medical Cen-
tre, a structured electronic literature search was composed,
using a combination of two main search criteria: microbiome
and the targeted skin condition (i.e. AD, SD/PC, HS, AV, UC
and PV). For each search term, all relevant keyword variations
were used in conjunction with free text word variations. The
search strategy was optimized for all consulted databases, tak-
ing into account the differences of the various controlled
vocabularies, as well as the differences of database-speciﬁc
technical variations (e.g. the use of quotation marks). The ﬁ-
nal search was performed on 29 September 2017, using bib-
liographic databases including PubMed (incl. MEDLINE),
Embase (OVID-version), Web of Science, Cochrane Library,
CENTRAL, Academic Search Premier and ScienceDirect.
Animal-only studies, reviews without original data, non-
English studies and case studies were excluded. Moreover,
culture-based methods were excluded since the objective of
this review was to explore the full microbiome proﬁle and rel-
ative abundances compared to other genus as biomarker. The
remaining studies were fully reviewed. The overall quality of
evidence was rated using pre-deﬁned criteria (group size, type
of control, method of sampling, serial sampling available,
well deﬁned metadata, analysis method). Grading of Recom-
mendations Assessment, Development and Evaluation (GRADE)
guidelines were used as guidance for rating the quality of ev-
idence [24]. This was done by two investigators indepen-
dently and the ﬁnal outcome was determined by discussion
once discrepancies occurred.
Results
The search resulted in 841 titles. After duplicates were re-
moved, 443 papers were screened for inclusion. Four-
hundred-and-one manuscripts were excluded based on the
exclusion criteria with mostly culture-based studies that were
not eligible. The remaining 42 studies were identiﬁed as using
nonculture-based methods to analyse microbiome popula-
tions in one of the targeted skin conditions and fully
reviewed, Figure 1. All 42 were included in the review, the
study characteristics can be found in Table 1.
Psoriasis vulgaris
In 10 studies, the cutaneous microbiome in PV patients was
investigated, Table 1 [25–34]. In addition tomicrobiota, these
studies have focused on the mycobiota. An increased
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diversity in the fungal ﬂora in psoriatic skin lesions, com-
pared to healthy skin was reported by Paulino et al. [25] and
Amaya et al. [26]. No differences in the abundance of speciﬁc
species was observed. Controversially, a signiﬁcant dichot-
omy between the relative abundances of speciﬁc Malassezia
species between healthy skin, and psoriatic skin lesions was
found by Takemoto et al. [32]. Similar inconsistencies in ﬁnd-
ings were also observed in those studies assessing the micro-
biota [28–31, 34].
Hidradenitis suppurativa
To date, only two studies have been published that investi-
gated the skin microbiome in HS (Table 1) [35, 36]. Both stud-
ies report a signiﬁcant dysbiosis in HS lesional skin with more
abundance of anaerobic genera. Five lesional microbiome
types were identiﬁed of which type 1 (Corynebacterium spe-
cies) and type IV (Porphyromonas and Peptoniphilus species)
were most prevalent [35]. Porphyromonas was also found as
predominantly abundant on lesional skin by Guet-Revillet
et al. [36], together with Prevotella species. In addition, clinical
severity signiﬁcantly correlated with Fusobacterium and
Parvimonas species variation in this study.
Ulcus cruris
The role of the skin microbiome in UCwas explored in 10 dif-
ferent studies, Table 1 [37–46]. Current research into UC
microbiome, comprises larger, longitudinal studies, com-
pared to those in PV and HS. The skin mycobiota of diabetic
foot ulcers was longitudinally assessed and was observed to
be highly heterogeneous over time and between subjects
while the diversity increased upon antibiotic treatment [45].
There have been similar efforts to reveal correlations between
patient metadata, treatment and/or clinical outcomes and
the cutaneousmicrobiome in studies investigating themicro-
biota in UC [38, 42–44, 46]. Overall, the most common found
genus in these studies was Staphylococcus, with Staphylococcus
aureus the most common species. Ulcer closing in diabetic pa-
tients was found to be positively correlated with higher mi-
crobial diversity and relative abundance of Proteobacteria,
while a relative abundance of Staphylococcus was correlated
negatively in a study by Gardner et al. [42]. Although Staphy-
lococcuswas consistently reported to be themost common ge-
nus, inconsistencies exist regarding other genus that are
important in CU.
Seborrheic dermatitis/Pityriasis capitis
Four case–control studies investigated the microbiome in SD
patients [47–50], Table 1. In general, Malassezia spp. were
found to be more abundant on dandruff scalp compared to
healthy scalp [47, 48, 50]. In addition to the mycobiota, a
dysbiosis in Staphylococcus and Propionibacterium spp. was de-
scribed inmicrobiota analysis [48, 50]. One of the four studies
did not ﬁnd a general association between Malassezia spp.
and SD but did ﬁnd a higher abundance ofM. globate in severe
SD patients [49].
Acne vulgaris
Five studies investigated the skin microbiome in patients
with AV, Table 1 [51–55]. Three (3) were case–control studies
and two (2) were small single-centre, controlled studies, of
whom one was a double-blind, randomized-controlled trial.
In general, all case–control studies demonstrated similarly
an increased microbial abundance of Propionibacterium acnes
in the skin microbiome of patients with AV, compared to
healthy [51–53]. In addition, an association between a spe-
ciﬁc P. acnes strains and acne affected skin, and healthy skin
respectively was demonstrated [51, 52]. Acne improved and
Propionibacterium abundance decreased after various treat-
ments, together with an increase of microbial diversity in
the two controlled studies. Moreover, a positive correlation
between Propionibacterium abundance and acne severity grade
was found [54, 55].
Atopic dermatitis
The skin microbiome in patients with AD was assessed in
11 studies, Table 1 [56–66]. A greater proportion of longitu-
dinal studies and 2 completed randomized controlled trials
were performed in AD patients. There is general consensus
across studies that skin affected by AD exhibits decreased
bacterial diversity, as a result of an increased abundance
of S. aureus [60–64, 66]. In particular, AD ﬂare ups were as-
sociated with an increased proportion of Staphyloccocus se-
quences, and S. aureus abundance correlated with disease
severity [60]. In line with these results, microbial diversity
in AD lesions was inversely correlated with overall eczema
severity as observed by the EASI [63], with several further
studies also reporting taxonomic normalization and in-
creased bacterial diversity in AD lesional skin, following
various treatments [60, 61, 63, 66].
Figure 1
Flowchart of the study
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Discussion
This systematic review provides an overview of the clinical
studies that have investigated nonculture skin microbiome
associated outcomes in AD, SD, AV, HS, PV and UC with the
goal to explore its potential as biomarker in early phase clin-
ical drug development with drug speciﬁc or disease speciﬁc
application, as also referred to as type 3 or type 6 biomarker
according to the classic deﬁnition of Danhof et al. [67].
Potential for microbiome as biomarker: AD and
AV
From our analysis, there is some preliminary evidence that
the skin microbiota may be a suitable disease speciﬁc bio-
marker for clinical trials of AD. This is due to the correlation
between Staphylococcus abundance, microbiome diversity
proﬁle and disease severity that seems to exist in multiple tri-
als, therewith complying with most of the criteria for a useful
biomarker, Table 2 [4]. Objective data on the change of the
microbiota may be valuable to support subjective AD efﬁcacy
scores in early phase clinical trials. However, it must be noted
that the cause and effect relationship between skin microbi-
ota dysbiosis and AD remains incompletely elucidated [68].
Currently, no evidence of beneﬁt of antimicrobial interven-
tions directed at reduction of Staphylococcus in patients with
AD exists, only in secondarily impetiginized AD [69–71]. As
multiple studies included in this review indicate that the skin
microbiota within an individual patient varies over time [60,
61, 63, 64], there is need for longitudinal, frequent sampling
and standard analysis studies. Nevertheless, it has proven its
potential value and is recommended to apply in AD clinical
trials, in particular when microbiota can serve also as drug-
speciﬁc biomarker, i.e. for drugs with antimicrobial activity
such as antimicrobial peptides that are currently in clinical
trials for AD.
In AV, a strong, positive correlation between
Propionibacterium and acne severity grade is reported [55].
Moreover, acne improved and Propionibacterium decreased
after treatment, while the microbial diversity increased
[54, 55]. Taking into account that a clear pathophysiological
role of P. acnes exists and antimicrobial interventions are ef-
fective in AV [72, 73], the adoption of the skin microbiome
as biomarker in acne drug development programmes is, al-
though still in its infancy, suggested by our review (Table 2).
Lesion clearance often takes a long time; therefore, the in-
clusion of microbiota is a valid option to monitor subclini-
cal treatment effects and restoration of normal bacterial
proﬁle, i.e. rebiosis. Although a small uncertainty remains
regarding the exact relationship between aberrations in the
skin microbiome and acne [74], we conclude that there is
deﬁnitely a potential for the microbiota as biomarker in
clinical trials (Table 2). Another option would be to culture
P. acnes instead of proﬁling the whole skin microbiota in
clinical trials; however, with this approach a comprehensive
overview and insight in the diversity will be missed.
PV, UC, hidradenitis and SD are lacking
evidence
Although dysbiosis in psoriasis seems to exist in the micro- as
well as the mycobiota, study ﬁndings are heterogeneous.
Wide variability in study design, sampling methods, control-
lable factors and sequencing techniques between groups, in
conjunction with small sample populations, could provide a
possible explanation for this. Therefore, no clear recommen-
dations can be made at this time. Future work focusing on se-
rial sampling and longitudinal studying of skin microbiome
populations it PV patients, may provide information on its
potential applicability as biomarker, Table 2. From a clinical
perspective, we know that antimicrobial and antifungal
agents are not successful in the treatment of psoriasis, which
suggests that it is less attractive to explore [75, 76]. However,
since immune dysregulation is the key of psoriasis and recent
investigations describe the extensive cross talk between the
immune system and the microbiome, there may still be po-
tential that should be explored [77]. For UC inconsistencies
in study design, sampling methods and the heterogeneity of
the disease group also limit the comparability of study ﬁnd-
ings. There appears to be a relationship between certain spe-
cies, types of ulcers and ulcer duration [42, 46]. However,
longitudinal studies with frequent standard sampling and
Table 2
Evaluation of the microbiome as clinical biomarker for each dermatological disease included in the review based on the criteria of a useful bio-















PV 10 Low – 0 0 0 Negative, more evidence needed
HS 2 Low + 0 0 + Negative, more evidence needed
UC 10 Low + 0 0 + Negative, more evidence needed
SD 4 Low – 0 0 + Negative, more evidence needed
AV 5 Moderate + + 0 + Positive
AD 11 Moderate + + 0 + Positive
AD, atopic dermatitis; AV, acne vulgaris; HS, hidradenitis suppurativa; PV, psoriasis vulgaris; SD/PC, seborrhoeic dermatitis/pityriasis capitis; UC, ulcus cruris
Scoring system indicated as follows: +, studies in general report a positive outcome; 0, no studies available; –, studies in general report a
negative outcome
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standard analysis procedures are necessary to make a recom-
mendation. The ﬁnding of dysbiosis in HS skin microbiome
mostly regarding anaerobic species that is mostly consistent
in two different studies opens up opportunities for the skin
microbiome as biomarker in this ﬁeld, Table 2 [35, 36]. How-
ever, future studies will have to conﬁrm this potential. In SD,
three different sequencing methods were used in the three
different studies [47, 49, 50]. This, together with the small
sample populations, single time point sampling and poor
study designs, might explain the heterogeneity in ﬁndings.
Since there is a clear evidence that antifungal agents such as
ketoconazole are effective in SD [78], it is recommended to
further explore the skin microbiome’s potential in this dis-
ease in future clinical trials.
Limitations and considerations
It is important to note that in all included studies, there was a
high variability in study design and sampling methods be-
tween groups, which makes comparisons of speciﬁc ﬁndings
difﬁcult. Case–control studies (25/42, 60%) dominate re-
search into the skin microbiome and skin disease. Patients
are compared with healthy controls, capturing microbial pro-
ﬁles at a particular time, but have little predictive value in de-
termining functionality, looking more at associations, and
not causation. The small patient sample sizes across all stud-
ies may fail to account for interindividual differences within
the study population. The poorly deﬁned inclusion and ex-
clusion criteria, with certain studies including actively
treated patients in their sample population, could also con-
found potential ﬁndings. The standardization of controllable
factors to reduce confounders was not well documented or
maybe not performed in most of the included studies. As sim-
ple factors including but not limiting of age, ethnicity, envi-
ronmental factors, soap use, hand-washing and the use of
topical (antimicrobial) agents before sampling have been
shown to alter microbial skin communities; documentation
of these metadata is essential to draw valid conclusions
[5, 8, 12, 60, 61, 79–81]. Multiple methods were used for
skinmicrobiome sampling across the studies (i.e. swabs, biop-
sies, tape strips, wound curettes). Interestingly, all have been
shown to exhibit a wide variation in biomass yield, micro-
bial proﬁle, human DNA contribution/contamination,
sampling depth and discomfort level for the test subject
[19, 62, 82–87]. In addition to the sampling method, the se-
lection of sampling sites and sampling frequency are impor-
tant factors that were not always considered in the
included studies. Consistent sampling of the same anatomi-
cal area of skin in all individuals in study cohorts is essential
in order to limit confounders, and allow for the accurate
comparison of skin microbiome populations. Moreover, re-
garding analysis, only consistent use of speciﬁc primers to
target speciﬁc hypervariable V regions, will allow for colla-
tion of data and comparison between multiple studies. It is
clear that broadly used analysis methods in this review as
shown in Table 1 count as a limitation for comparison.
Taken all the above together, based on the level of evidence
it is clear that our recommendations should be made with
some caution. A standard approach for skin microbiome
study design, collection, storage, processing and analysis as
proposed by Kong et al. should be followed in future studies
[17]. However, although the list of limitations and some-
times poor evidence might be assessed as a weak recommen
dation for the inclusion of cutaneous microbiome in der-
matological trials, the recent ﬁnding that the gut
microbiome partially explains the response/nonresponse
to PD-1 immunotherapy in different cancer patients will
foster research into microbiome in general [88, 89]. In ad-
dition, the relation between the gut microbiome in inﬂam-
matory bowel disease and response to inﬂiximab was also
recently highlighted [90]. In particular, when considering
the reports about the role of the gut-skin axis that might
inﬂuence many diseases including the here investigated
skin disorders [91–93].
Conclusion
Only a small number of studies have consistently reported
the cutaneous microbiome for skin diseases and chronic
wounds. Our ﬁndings reveal that for two indications – AD
and AV – there is preliminary evidence to support implemen-
tation of the skin microbiome as biomarker in early phase
clinical trials. For PV, UC, SD and HS, there is insufﬁcient ev-
idence. More standardized microbiome-directed studies
studying the effect of current treatments on the microbiome
are needed to draw conclusions.
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